tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Novavax 2025-2026 Formula COVID-19 vaccine approved in U.S.
The FlyNovavax 2025-2026 Formula COVID-19 vaccine approved in U.S.
2d ago
SNY
NVAX
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe Fly
Buy/Sell: Wall Street’s top 10 stock calls this week
7d ago
LI
CVS
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
7d ago
SNY
REGN
Sanofi’s New Vaccine Trial: A Potential Game-Changer for Infant Health
PremiumCompany Announcements
Sanofi’s New Vaccine Trial: A Potential Game-Changer for Infant Health
7d ago
SNY
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
PremiumCompany Announcements
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
7d ago
SNY
Sanofi’s Promising Phase 2a Diabetes Study: A Potential Game-Changer?
PremiumCompany AnnouncementsSanofi’s Promising Phase 2a Diabetes Study: A Potential Game-Changer?
7d ago
SNY
Sanofi’s Phase 3 Study on PCV21 Vaccine: A Potential Game-Changer in Pediatric Health
Premium
Company Announcements
Sanofi’s Phase 3 Study on PCV21 Vaccine: A Potential Game-Changer in Pediatric Health
7d ago
SNY
Regeneron and Sanofi’s Itepekimab Study: A Potential Game-Changer for COPD Treatment
Premium
Company Announcements
Regeneron and Sanofi’s Itepekimab Study: A Potential Game-Changer for COPD Treatment
8d ago
SNY
REGN
Sanofi’s Phase 3 Study on Riliprubart for CIDP: A Potential Game-Changer
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Riliprubart for CIDP: A Potential Game-Changer
9d ago
SNY
Sanofi’s SAR445877 Study: A New Frontier in Cancer Treatment
PremiumCompany Announcements
Sanofi’s SAR445877 Study: A New Frontier in Cancer Treatment
9d ago
SNY
Sanofi’s Phase 3 Study on PCV21 Vaccine: A Potential Game-Changer for Infant Immunization
PremiumCompany Announcements
Sanofi’s Phase 3 Study on PCV21 Vaccine: A Potential Game-Changer for Infant Immunization
9d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Prurigo Nodularis
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Prurigo Nodularis
9d ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Chronic Urticaria
PremiumCompany AnnouncementsRegeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Chronic Urticaria
9d ago
SNY
REGN
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
Premium
Company Announcements
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
9d ago
SNY
Novavax downgraded to Underperform at BofA on ‘murky outlook’
Premium
The Fly
Novavax downgraded to Underperform at BofA on ‘murky outlook’
9d ago
SNY
NVAX
Sanofi’s Phase 3 Study on Riliprubart: A Potential Game-Changer for CIDP Treatment
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Riliprubart: A Potential Game-Changer for CIDP Treatment
10d ago
SNY
Sanofi’s SAR445877 Study: A Potential Breakthrough in Cancer Treatment
PremiumCompany Announcements
Sanofi’s SAR445877 Study: A Potential Breakthrough in Cancer Treatment
10d ago
SNY
Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
PremiumThe Fly
Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
14d ago
AMD
AZN
Sanofi’s Teplizumab Study: A Closer Look at Real-World Impact on Type 1 Diabetes
PremiumCompany Announcements
Sanofi’s Teplizumab Study: A Closer Look at Real-World Impact on Type 1 Diabetes
14d ago
SNY
Sanofi’s Phase 3 Study on Belumosudil for CLAD: A Potential Game-Changer
PremiumCompany AnnouncementsSanofi’s Phase 3 Study on Belumosudil for CLAD: A Potential Game-Changer
14d ago
SNY
Sanofi’s New Phase 2a Study: A Potential Game-Changer in Kidney Disease Treatment
Premium
Company Announcements
Sanofi’s New Phase 2a Study: A Potential Game-Changer in Kidney Disease Treatment
14d ago
SNY
Sanofi’s Dupilumab Study: A Closer Look at Long-term Treatment for Prurigo Nodularis
Premium
Company Announcements
Sanofi’s Dupilumab Study: A Closer Look at Long-term Treatment for Prurigo Nodularis
14d ago
SNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >